Herzog TJ - Search Results

1

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Monk BJ, et al. Among authors: herzog tj. Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17. Lancet Oncol. 2014. PMID: 24950985 Clinical Trial.

2

Topotecan in platinum- and paclitaxel-resistant ovarian cancer.

Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Swisher EM, et al. Among authors: herzog tj. Gynecol Oncol. 1997 Sep;66(3):480-6. doi: 10.1006/gyno.1997.4787. Gynecol Oncol. 1997. PMID: 9299264 Clinical Trial.

3

Workshop: options for therapy in ovarian cancer.

Herzog TJ, Holloway RW, Stuart GC. Herzog TJ, et al. Gynecol Oncol. 2003 Sep;90(3 Pt 2):S45-50. doi: 10.1016/s0090-8258(03)00473-6. Gynecol Oncol. 2003. PMID: 13129496 Review.

4

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. Horowitz NS, et al. Among authors: herzog tj. Gynecol Oncol. 2004 Jul;94(1):67-73. doi: 10.1016/j.ygyno.2004.03.047. Gynecol Oncol. 2004. PMID: 15262121

5

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

6

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.

Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Gallion H, et al. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201. doi: 10.1111/j.1525-1438.2006.00301.x. Int J Gynecol Cancer. 2006. PMID: 16445633

7

The role of maintenance therapy and novel taxanes in ovarian cancer.

Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. Herzog TJ, et al. Gynecol Oncol. 2006 Aug;102(2):218-25. doi: 10.1016/j.ygyno.2005.12.001. Epub 2006 Feb 7. Gynecol Oncol. 2006. PMID: 16460787 Review.

8

A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.

Herzog TJ, Coleman RL, Guerrieri JP Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. Herzog TJ, et al. Am J Obstet Gynecol. 2006 Aug;195(2):445-53. doi: 10.1016/j.ajog.2006.01.039. Epub 2006 Apr 19. Am J Obstet Gynecol. 2006. PMID: 16626607 Clinical Trial.

9

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. Gossner G, et al. Among authors: herzog tj. Gynecol Oncol. 2006 Oct;103(1):212-8. doi: 10.1016/j.ygyno.2006.02.026. Epub 2006 May 3. Gynecol Oncol. 2006. PMID: 16677696

10

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Herzog TJ, et al. Gynecol Oncol. 2006 Nov;103(2):637-41. doi: 10.1016/j.ygyno.2006.04.014. Epub 2006 Jun 15. Gynecol Oncol. 2006. PMID: 16781766 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page